These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 3622317)

  • 1. The haemodynamic and anti-ischaemic effects of a single tablet of 80 mg isosorbide dinitrate in slow-release formulation and a review of nitrate tolerance.
    Silber S; Vogler AC; Krause KH; Theisen K
    Drugs; 1987; 33 Suppl 4():69-79. PubMed ID: 3622317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction and circumvention of nitrate tolerance applying different dosage intervals.
    Silber S; Vogler AC; Krause KH; Vogel M; Theisen K
    Am J Med; 1987 Nov; 83(5):860-70. PubMed ID: 3674093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal nitrate therapy with a once-daily sustained-release formulation of isosorbide mononitrate.
    Waller DG
    J Cardiovasc Pharmacol; 1999 Aug; 34 Suppl 2():S21-7; discussion S29-31. PubMed ID: 10499557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitrates: why and how should they be used today? Current status of the clinical usefulness of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate.
    Silber S
    Eur J Clin Pharmacol; 1990; 38 Suppl 1():S35-51. PubMed ID: 2113003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitrate tolerance: hemodynamic effects of intravenous isosorbide dinitrate after sustained oral isosorbide dinitrate administration.
    Kumagae H; Koiwaya Y; Tanaka K
    Clin Ther; 1990; 12(1):31-43. PubMed ID: 2328526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-ischemic effects of first and second dose of 20 mg isosorbide dinitrate administered 5 hours apart: attenuation of effects despite rising plasma concentration.
    Lehmann G; Reiniger G; Wolf H; Beyerle A; Rudolph W
    Cardiovasc Drugs Ther; 1995 Apr; 9(2):339-45. PubMed ID: 7662601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circadian investigation of interval therapy with isosorbide dinitrate in coronary heart disease.
    Wortmann A; Bachmann K; Meinhold M
    Eur Heart J; 1988 Jan; 9 Suppl A():119-24. PubMed ID: 3409908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of swallowed isosorbide dinitrate on blood pressure, heart rate and exercise capacity in patients with coronary artery disease.
    Glancy DL; Richter MA; Ellis EV; Johnson W
    Am J Med; 1977 Jan; 62(1):39-46. PubMed ID: 319662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. When does nitrate tolerance develop? What dosages and which intervals are necessary to ensure maintained effectiveness?
    Rudolph W; Dirschinger J; Reiniger G; Beyerle A; Hall D
    Eur Heart J; 1988 Jan; 9 Suppl A():63-72. PubMed ID: 3137072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [4 different nitrate preparations with regard to the possible development of tolerance in long-term treatment].
    Mertens HM; Ohlmeier H; Mannebach H; Kabelitz K; Gleichmann U
    Herz; 1985 Jun; 10(3):172-81. PubMed ID: 3926614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients.
    Döring G
    J Cardiovasc Pharmacol; 1992; 20 Suppl 3():S74-81. PubMed ID: 1282180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nitrate tolerance.
    Parker JO
    Am J Cardiol; 1987 Nov; 60(15):44H-48H. PubMed ID: 3120566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of long-term oral administration of isosorbide dinitrate on the antianginal response to nitroglycerin. Absence of nitrate cross-tolerance and self-tolerance shown by exercise testing.
    Lee G; Mason DT; De Maria AN
    Am J Cardiol; 1978 Jan; 41(1):82-7. PubMed ID: 414612
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparative clinical trial of isosorbide 5-mononitrate and sustained-release isosorbide dinitrate in ischaemic heart disease.
    Neuhaus R; Johnen R; Vydra L; Solbach C
    Pharmatherapeutica; 1986; 4(8):486-95. PubMed ID: 3086899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemodynamic measurements and exercise testing to assess the development of tolerance against slow-release isosorbide dinitrate.
    Weidemann H; Schuon J; Schober B
    Z Kardiol; 1983; 72 Suppl 3():229-32. PubMed ID: 6666226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma profile and haemodynamic tolerance to isosorbide-5-mononitrate in controlled-release form.
    Jähnchen E
    Br J Clin Pharmacol; 1992; 34 Suppl 1(Suppl 1):15S-17S. PubMed ID: 1633073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of nitrate tolerance in individual patients with stable angina pectoris in various phases of therapy with oral isosorbide dinitrate].
    Kośmicki M; Szwed H; Kowalik I; Sadowski Z
    Pol Merkur Lekarski; 2002 Jul; 13(73):52-5. PubMed ID: 12362508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of tolerance with regard to the anti-ischemic effect of isosorbide dinitrate in regular multiple daily administration].
    Reiniger G; Blasini R; Brügmann U; Rudolph W
    Herz; 1984 Jun; 9(3):146-52. PubMed ID: 6430768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained hemodynamic and antianginal effects of high dose oral isosorbide dinitrate.
    Aronow S
    Nouv Presse Med; 1980 Sep; 9(34 Suppl):2483-6. PubMed ID: 7422537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Nycthemeral changes in plasma concentrations of active nitrate derivatives. Comparison of a single dose of LP 60mg isosobide dinitrate and LP 20mg isosobide dinitrate administered 3 times daily].
    Ollivier JP; Pello JY; Auclert L; Dorléac D; Guillou J; Olive G
    Arch Mal Coeur Vaiss; 1992 Apr; 85 Spec No 1():17-20. PubMed ID: 1530423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.